No connection

Search Results

RPRX

BEARISH
$50.0 Live
Royalty Pharma plc · NASDAQ
Target $51.78 (+3.6%)
$31.58 52W Range $50.0
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 19, 2026
Market cap
$29.64B
P/E
28.09
ROE
13.2%
Profit margin
32.4%
Debt/Equity
0.92
Dividend yield
1.88%

AI Analysis

AI-powered fundamental assessment

Confidence
85%
RPRX exhibits a stable but mediocre Piotroski F-Score of 4/9, indicating average financial health without strong momentum. The stock is significantly overvalued, trading at $50.00 despite a Graham Number of $24.60 and an Intrinsic Value of $36.49. Aggressive insider selling by the CFO and a sharp decline in recent Q/Q EPS growth (-67.5%) signal significant internal caution. While analyst sentiment remains a 'buy', the deterministic data and valuation gap suggest a high risk of a price correction.

Key Strengths

Exceptional operating margins (57.68%) and profit margins (32.42%)
Strong liquidity position with a current ratio of 2.40
Low forward P/E ratio (9.09) suggesting expected earnings recovery
Consistent historical profitability and positive ROE (13.20%)
Strong 1-year price appreciation (+57%)

Key Risks

Severe overvaluation relative to Graham Number ($24.60) and Intrinsic Value ($36.49)
Aggressive insider selling with 14 sell transactions and 0 buys
Sharp deterioration in recent Q/Q EPS growth (-67.5%)
High PEG ratio (2.78) indicating price is decoupled from growth rates
Negative earnings surprise trend over the last 4 quarters (-17.11% average)
AI Fair Value Estimate
Based on comprehensive analysis
$33.5
-33.0% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
48
Moderate
Value
30
Future
45
Past
60
Health
55
Dividend
50
AI Verdict
Overvalued with deteriorating momentum
Key drivers: Valuation gap, Insider selling, EPS contraction
Confidence
90%
Value
30/100

Current price $50.00 vs Graham $24.60 and Intrinsic $36.49

Positives
  • Low forward P/E
Watchpoints
  • Price far exceeds Graham Number
  • High P/S ratio (12.46)
  • High PEG ratio
Future
45/100

Growth rates are modest and showing recent volatility

Positives
  • Positive YoY earnings growth (9%)
Watchpoints
  • Recent Q/Q EPS crash (-67.5%)
  • Low revenue growth (4.8%)
Past
60/100

Strong price performance masking fundamental deceleration

Positives
  • Strong 1Y and 3Y price returns
  • Consistent historical earnings beats
Watchpoints
  • Recent trend of missing estimates
Health
55/100

Piotroski F-Score 4/9; Altman Z-Score not provided

Positives
  • Healthy current ratio (2.40)
  • Manageable Debt/Equity (0.92)
Watchpoints
  • Piotroski F-Score of 4/9 is only 'Stable'
Dividend
50/100

Moderate dividend strength (40/100)

Positives
  • Sustainable payout ratio (49.44%)
Watchpoints
  • Low dividend yield (1.88%)

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$50.0
Analyst Target
$51.78
Upside/Downside
+3.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for RPRX and closest competitors.

Updated 2026-04-17
RPR
Royalty Pharma plc
Primary
5Y
+34.5%
3Y
+51.1%
1Y
+57.0%
6M
+36.6%
1M
+9.2%
1W
+4.4%
NTR
Natera, Inc.
Peer
5Y
+93.7%
3Y
+306.2%
1Y
+36.5%
6M
+15.5%
1M
+4.8%
1W
-1.7%
BII
Biogen Inc.
Peer
5Y
-34.2%
3Y
-34.1%
1Y
+34.0%
6M
+30.9%
1M
-2.5%
1W
-0.3%
GEH
GE HealthCare Technologies Inc.
Peer
5Y
+22.2%
3Y
-9.0%
1Y
+12.5%
6M
-1.6%
1M
+0.3%
1W
+3.6%
INS
Insmed Incorporated
Peer
5Y
+402.3%
3Y
+817.7%
1Y
+138.9%
6M
-4.6%
1M
+11.1%
1W
-4.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
28.09
Forward P/E
9.09
PEG Ratio
2.78
P/B Ratio
3.31
P/S Ratio
12.46
EV/Revenue
13.87
EV/EBITDA
21.1
Market Cap
$29.64B

Profitability

Profit margins and return metrics

Profit Margin 32.42%
Operating Margin 57.68%
Gross Margin 112.44%
ROE 13.2%
ROA 5.15%

Growth

Revenue and earnings growth rates

Revenue Growth +4.8%
Earnings Growth +9.0%
Q/Q Revenue Growth +4.78%
Q/Q Earnings Growth +2.9%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.92
Moderate
Current Ratio
2.4
Strong
Quick Ratio
2.39
Excellent
Cash/Share
$1.49

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.6B
Op. Margin
62.4%
Net Margin
34.4%
Total Assets
$19.6B
Liabilities
$9.9B
Equity
$6.5B
Debt/Equity
1.53x
Operating CF
$0.8B
Free Cash Flow
$0.8B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-02-11
$0.38
-74.3% surprise
2025-11-05
$1.17
+12.5% surprise
2025-08-06
$1.14
+10.5% surprise

Healthcare Sector Comparison

Comparing RPRX against 447 companies in the Healthcare sector (26 bullish, 140 neutral, 281 bearish)
P/E Ratio
28.09
This Stock
vs
87.83
Sector Avg
-68.0% (Discount)
Return on Equity (ROE)
13.2%
This Stock
vs
-97.42%
Sector Avg
-113.6% (Below Avg)
Profit Margin
32.42%
This Stock
vs
-14.95%
Sector Avg
-316.8% (Weaker)
Debt to Equity
0.92
This Stock
vs
3.06
Sector Avg
-69.8% (Less Debt)
Revenue Growth
4.8%
This Stock
vs
147.85%
Sector Avg
-96.8% (Slower)
Current Ratio
2.4
This Stock
vs
4.68
Sector Avg
-48.6% (Weaker)

Similar Companies

Peer comparison within the same industry

RPRX Royalty Pharma plc
BEARISH
Mkt Cap
$29.6B
P/E
28.1
ROE
13.2%
Price
$50.0
NTRA Natera, Inc.
NEUTRAL
Mkt Cap
$29.4B
P/E
-
ROE
-14.3%
Price
$207.19
 Compare with RPRX
BIIB Biogen Inc.
NEUTRAL
Mkt Cap
$26.9B
P/E
20.8
ROE
7.4%
Price
$183.33
 Compare with RPRX
GEHC GE HealthCare...
NEUTRAL
Mkt Cap
$33.3B
P/E
16.2
ROE
22.4%
Price
$72.91
 Compare with RPRX
INSM Insmed Incorporated
BEARISH
Mkt Cap
$33.4B
P/E
-
ROE
-249.3%
Price
$154.81
 Compare with RPRX

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

COYNE TERRANCE P
Chief Financial Officer
Sell
2026-04-01
34,791 shares · $1,681,512
BASSLER BONNIE L
Director
Stock Award
2026-03-31
815 shares · $37,471
COYNE TERRANCE P
Chief Financial Officer
Sell
2026-03-23
34,791 shares · $1,583,989
COYNE TERRANCE P
Chief Financial Officer
Sell
2026-03-02
34,791 shares · $1,627,534
COYNE TERRANCE P
Chief Financial Officer
Sell
2026-02-23
34,791 shares · $1,576,606
LEGORRETA PABLO G
Chief Executive Officer
Stock Award
2026-02-11
157,828 shares
HITE CHRISTOPHER D.
Officer
Stock Award
2026-02-11
26,626 shares
COYNE TERRANCE P
Chief Financial Officer
Stock Award
2026-02-11
26,626 shares
URIST MARSHALL J.
Officer
Stock Award
2026-02-11
19,970 shares
COYNE TERRANCE P
Chief Financial Officer
Sell
2026-02-04
243,541 shares · $10,360,814
URIST MARSHALL J.
Officer
Sell
2026-01-30
20,000 shares · $821,810
URIST MARSHALL J.
Officer
Sell
2026-01-23
20,000 shares · $805,110
COYNE TERRANCE P
Chief Financial Officer
Sell
2026-01-20
69,582 shares · $2,737,940
URIST MARSHALL J.
Officer
Sell
2026-01-16
20,000 shares · $790,346
URIST MARSHALL J.
Officer
Sell
2026-01-09
20,000 shares · $815,634
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-04-13

Repare Therapeutics filed a current report to disclose material corporate developments, likely pertaining to first-quarter financial results or clinical trial updates.

DEF 14A
DEF 14A
2026-04-10

RPRX filed a definitive proxy statement on April 10, 2026, providing shareholders with necessary information to vote on matters at the company's annual meeting.

8-K
8-K
2026-02-11

Repare Therapeutics filed a current report on February 11, 2026, likely announcing its fourth quarter and full-year financial results.

10-K
10-K
2026-02-11

RPRX filed its annual 10-K report on February 11, 2026, providing comprehensive disclosures on its business operations and financial condition. The filing includes detailed sections on risk factors and management's discussion and analysis of results of operations.

8-K
8-K
2025-12-22
8-K
8-K
2025-12-22
10-Q
10-Q
2025-11-05

Repare Therapeutics (RPRX) filed its Form 10-Q on November 5, 2025. The filing includes a section on risk factors under Item 1A, although specific financial highlights and detailed risk descriptions were not provided in the available excerpt.

8-K
8-K
2025-11-05

Repare Therapeutics filed an 8-K on November 5, 2025, likely to report its third-quarter financial results or a material clinical development.

8-K
8-K
2025-09-16
8-K
8-K
2025-08-13

Repare Therapeutics filed an 8-K likely reporting its second-quarter financial results or a material corporate update.

8-K
8-K
2025-08-06
10-Q
10-Q
2025-08-06
8-K
8-K
2025-07-17
8-K
FORM 8-K
2025-05-19
8-K
8-K
2025-05-12
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
9 analysts
Morgan Stanley
2026-04-10
Maintains
Overweight Overweight
Citigroup
2026-01-27
Maintains
Buy Buy
TD Cowen
2025-12-11
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning RPRX from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile